News Archives - Page 3 of 16 - Halberd Corporation

Mar 30 2023

Halberd and Mississippi State University (MSU) Sign Agreement to Conduct Pre-Clinical Model Tests of Nasal Spray to Block Negative Effects of Head Trauma

By Admin|2023-03-29T19:43:38-04:00March 30th, 2023|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA March 30, 2023 – Halberd Corporation (OTC-PINK: "HALB”) and Mississippi State University (MSU) signed an agreement outlining the testing in pre-clinical models which will be conducted at MSU. The testing will focus on Halberd’s patent-pending nasal spray designed to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining ...

Mar 21 2023

Halberd Eradicates All Strains of Antibiotic Resistant E. Coli Provided by the CDC at Youngstown State University

By Admin|2023-03-21T18:30:21-04:00March 21st, 2023|Investor News, Medical, News, Press Releases, Uncategorized|0 Comments

Jackson Center, PA, March 21, 2023 – Halberd Corporation (OTC PINK:HALB), leading up to the scheduled meeting with the Centers for Disease Control (CDC) on March 29, 2023, is pleased to report it has successfully eradicated all of the strains of antibiotic resistant E. coli samples previously provided by the CDC. Using Halberd’s patented extracorporeal ...

Feb 21 2023

Halberd Demonstrates Simultaneous Eradication of Multiple Strains of CDC Provided Antibiotic Resistant Bacteria

By Admin|2023-02-21T05:34:56-05:00February 21st, 2023|Featured, Investor News, Medical, News, Press Releases|0 Comments

Killed 99.5% of a mixture of four strains of E. coli bacteria in buffer solution in-vitro Jackson Center, PA, February 21, 2023 – Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to simultaneously eradicate multiple strains of antibiotic resistant E. coli provided by the CDC in under ten minutes. Halberd’s patented extracorporeal process and patent-pending ...

Feb 13 2023

Halberd Corporation Announces Breakthrough in Candida auris Treatment

By Admin|2023-02-12T19:53:01-05:00February 13th, 2023|Investor News, Medical, News, Press Releases|0 Comments

Halberd Demonstrates Eradication of Candida Auris Fungus in as little as five minutes. Jackson Center, PA, February 13, 2023 – Halberd Corporation (OTC PINK:HALB) a leading provider of innovative healthcare solutions, is proud to announce a major breakthrough in the development of a treatment for Candida auris infections. Candida auris is one of the antibiotic ...

Feb 8 2023

Halberd Demonstrates Eradication of CDC Provided Antibiotic Resistant Bacteria

By Admin|2023-02-08T04:58:45-05:00February 8th, 2023|Investor News, Medical, News, Press Releases|0 Comments

Youngstown State University (YSU) Professors and Student Scholars Successfully Conduct Research Testing Jackson Center, PA, February 8, 2023 – Halberd Corporation (OTC PINK:HALB) has demonstrated its patent-pending extracorporeal laser eradication process is capable of eliminating antibiotic resistant strains of CDC provided bacteria samples. Previously, Halberd demonstrated success in eliminating Escherichia coli and other Gram-Negative bacteria ...

Jan 24 2023

Halberd Agrees to Animal Testing at Mississippi State University

By Admin|2023-01-23T17:04:28-05:00January 24th, 2023|Investor News, Medical, News, Press Releases|0 Comments

College of Veterinary Medicine to conduct testing Jackson Center, PA January 24, 2023 – Halberd Corporation’s (OTC-PINK: "HALB”) has agreed to conduct animal testing at Mississippi State University’s (MSU) animal testing laboratory. The Department of Comparative Biomedical Sciences in the College of Veterinary Medicine and the Department of Biomedical Engineering at Mississippi State University will ...

Dec 6 2022

Halberd Receives Several Strains of Antibiotic Resistant Bacteria from CDC to Test Laser Eradication

By Admin|2022-12-05T19:18:54-05:00December 6th, 2022|Featured, Investor News, News, Press Releases|0 Comments

Halberd’s method shown previously to be effective on multiple strains of antibiotic resistant bacteria to be tested on CDC strains. Jackson Center, PA December 6, 2022 – Halberd Corporation (OTC-PINK: "HALB”) has received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic resistant bacteria (ARB). Halberd will utilize its laser eradication ...

Dec 5 2022

“The Street Podcast” Features Halberd’s “Groundbreaking” Cancer Treatment Approach. Listen Now!

By Admin|2022-12-04T16:15:09-05:00December 5th, 2022|Featured, Investor News, Medical, News|0 Comments

CEO William Hartman and CTO Mitchell Felder report successful application of Halberd’s patented methodology for Cancer Antigen Eradication Treatment. Jackson Center, PA December 5, 2022 – Halberd Corporation’s (OTC-PINK: "HALB”) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr. Mitchell S. Felder, interviewed on "The Street Reports," discuss their groundbreaking accomplishments, successfully ...

Nov 30 2022

Halberd Team Produces Peer Reviewed Article on Antibody Against Covid-19 Omicron Variant

By Admin|2022-11-30T19:22:58-05:00November 30th, 2022|Featured, Investor News, Medical, News|0 Comments

UPDATED. Boosts effectiveness by 44.4%% of commercially available Covid antibody in cocktail Jackson Center, PA November 30, 2022 – Halberd Corporation’s (OTC-PINK: "HALB”) Covid research has led to a scientific article titled, “A Novel Plant-Made Monoclonal Antibody Enhances the Synergetic Potency of an Antibody Cocktail Against The SARS-Cov-2 Omicron Variant.” The article has been peer ...

Nov 17 2022

Halberd Corporation Achieves Groundbreaking Pre-Clinical Endpoint By Eradicating Cancer Disease Antigen Linked to Breast Cancer

By Admin|2022-11-17T05:15:05-05:00November 17th, 2022|Featured, Investor News, Medical, News|0 Comments

Halberd Successful In Laboratory Tests In Eradicating All Five of The Top Cancer Disease Antigens Attempted To Date Jackson Center, PA, November 17, 2022 – Halberd Corporation (OTC-PINK: "HALB”) researchers have been successful in in-vitro laboratory tests using buffer solution in eradicating the cancer disease antigen CTLA-4 through the use of laser emissive energy in ...

Previous 234 Next